Emergence and persistence of beta-lactamase-producing bacteria in the upper respiratory tract in children treated with beta-lactam antibiotics

Am J Med. 1990 May 14;88(5A):51S-55S. doi: 10.1016/0002-9343(90)90263-d.

Abstract

Purpose: To assess the ecologic impact, in terms of selection of beta-lactamase-producing respiratory tract bacteria, of a single course of peroral beta-lactam antibiotics.

Patients and methods: One-hundred fifty consecutive children with clinical signs of bacterial respiratory tract infection were randomly assigned to a seven-day course of treatment with either penicillin V, amoxicillin, or cefaclor. Bacteriologic specimens were collected before treatment, at its termination, and at follow-up four weeks later.

Results: All three drugs investigated caused a similar increase in beta-lactamase-producing bacteria, both in absolute and relative terms, an increase that persisted over a period of at least one month after completion of treatment.

Conclusion: Penicillin V, amoxicillin, and cefaclor all act as selective agents for beta-lactamase-producing bacteria in the upper respiratory tract. Treatment with a peroral beta-lactam antibiotic puts patients at risk of becoming persistent carriers of beta-lactamase-producing bacteria.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteria / enzymology*
  • Bacterial Infections / drug therapy
  • Cefaclor / therapeutic use
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Penicillin V / therapeutic use
  • Random Allocation
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / microbiology*
  • beta-Lactamases / biosynthesis*

Substances

  • Anti-Bacterial Agents
  • Cefaclor
  • Amoxicillin
  • beta-Lactamases
  • Penicillin V